Show simple item record

dc.contributor.authorRibeiro, G
dc.date.accessioned2014-12-22T15:45:48Z
dc.date.available2014-12-22T15:45:48Z
dc.date.issued1983-11
dc.identifier.citationTamoxifen in the treatment of male breast carcinoma. 1983, 34 (6):625-8 Clin Radiolen
dc.identifier.issn0009-9260
dc.identifier.pmid6673881
dc.identifier.urihttp://hdl.handle.net/10541/337550
dc.description.abstractTwenty-four patients with advanced carcinoma of the male breast have been treated with tamoxifen citrate (Nolvadex). An objective regression rate of 37.5% was obtained, with five complete and four partial responses. In addition, two patients had stabilisation of their disease for 24 months each. Regression of disease was noted in soft-tissue disease, bone and lung metastases. The duration of response ranged from 8 months to 60 months with a mean of 21 months. In view of the singular lack of side-effects and the age group of the patients (mean age 63 years), it is suggested that tamoxifen should be the first line of endocrine therapy before orchidectomy or adrenalectomy.
dc.language.isoenen
dc.rightsArchived with thanks to Clinical radiologyen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshBreast Neoplasms
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Metastasis
dc.subject.meshReceptors, Estrogen
dc.subject.meshReceptors, Progesterone
dc.subject.meshTamoxifen
dc.titleTamoxifen in the treatment of male breast carcinoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Radiotherapy, The Christie Hospital & Holt Radium Institute, Manchesteren
dc.identifier.journalClinical Radiologyen
html.description.abstractTwenty-four patients with advanced carcinoma of the male breast have been treated with tamoxifen citrate (Nolvadex). An objective regression rate of 37.5% was obtained, with five complete and four partial responses. In addition, two patients had stabilisation of their disease for 24 months each. Regression of disease was noted in soft-tissue disease, bone and lung metastases. The duration of response ranged from 8 months to 60 months with a mean of 21 months. In view of the singular lack of side-effects and the age group of the patients (mean age 63 years), it is suggested that tamoxifen should be the first line of endocrine therapy before orchidectomy or adrenalectomy.


This item appears in the following Collection(s)

Show simple item record